Enzymatica AB (publ) (ENZY.ST) Stock Analysis & Winston Score

Enzymatica is a Swedish healthcare company that makes over-the-counter cold and flu products. Its main product is ColdZyme, a mouth spray that creates a protective barrier in the throat to help reduce the chance of getting a cold or lessen how bad symptoms are. The company sells primarily to everyday consumers through pharmacies and retail stores, mainly in Europe. Enzymatica earns money by selling its products directly to retailers and distributors, who then sell them to shoppers. The company is headquartered in Lund, Sweden, and operates mostly in Scandinavian and European markets, though it has been working to expand internationally. Its core technology is based on an enzyme called trypsin, derived from deep-sea cod, which gives ColdZyme a somewhat unique scientific angle compared to standard cold remedies. However, the company is currently unprofitable with a deeply negative operating margin, and its biggest challenge is scaling sales fast enough to cover its ongoing research and commercial costs.